2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine | 1196396-14-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine
• 英文别名: 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyridine
• CAS: 1196396-14-1
• 化学式: C₁₇H₂₀BNO₃
• 分子量: 297.162
• InChiKey: XTVMUTCVPPCEEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.17
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 氢溴酸 、 potassium carbonate 、 溶剂黄146 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 8.5h， 生成 1-[(2S)-2-[8-amino-1-(4-pyridin-2-yloxyphenyl)imidazo[1,5-a]pyrazin-3-yl]pyrrolidin-1-yl]but-2-yn-1-one
  参考文献：
  名称：

  IMIDAZOPYRIDINAMINE PHENYL DERIVATIVE AND USE THEREOF

  摘要：

  公开号：

  EP3480199B1
• 作为产物：
  描述：

  2-氟吡啶 在 四(三苯基膦)钯 、 potassium carbonate 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyridine
  参考文献：
  名称：

  IMIDAZOPYRIDINAMINE PHENYL DERIVATIVE AND USE THEREOF

  摘要：

  公开号：

  EP3480199B1

文献信息

• TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1
  申请人：Braun Alain Jean

  公开号：US20110294809A1

  公开（公告）日：2011-12-01

  The invention relates to tropane urea derivatives of general formula (I) and to the application thereof as modulators of the activity of 11β-hydroxysteroid dehydrogenose type 1 (11βHSD1).

  本发明涉及一类通式（I）的莨菪脲衍生物，以及它们作为11β-羟基类固醇脱氢酶1型（11βHSD1）活性调节剂的应用。
• [EN] FUSED HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2012018909A1

  公开（公告）日：2012-02-09

  The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound represented by the formula (1'): wherein, Ring A' represents an optionally substituted pyridine ring, an optionally substituted pyridazine ring, a pyrimidine ring, or 10 a pyrazine ring, R1' represents (1) wherein, R1a' represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2 represents a bond, -S-, -0-, -CO-, an optionally substituted methylene group, or -NRa'- (Ra' represents a hydrogen atom, or an optionally substituted C1-6 alkyl group), and Ring B1' represents an optionally further substituted 6- to 10- membered aromatic hydrocarbon ring, or an optionally further substituted 5- to 10-membered aromatic heterocyclic ring, or alternatively, L' and R1a' may be taken together to form an optionally substituted bicyclic or tricyclic fused heterocyclic group, or (2), wherein, R1b' represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2' represents an optionally substituted benzene ring, an optionally substituted pyridine ring, an optionally substituted pyrimidine ring, an optionally substituted pyrazine ring, or an optionally substituted pyridazine ring, Ring D' represents an optionally further substituted 5- or 6- membered ring, R2' represents a hydrogen atom, or a substituent, X' represents =N- or =CRb'- (Rb' represents a hydrogen atom, or a substituent), _ _ _ _ _ represents that Rb' and R2' may form, taken together with the carbon atom and the nitrogen atom to which they are each adjacent, an optionally substituted 5- to 7-membered ring when.X' is =CRb'-, or a salt thereof.

  本发明提供了一种具有PDE 10A抑制作用的化合物，可用作预防或治疗精神分裂症等疾病的药物。化合物的结构如下（1'）：其中，环A'代表可选择取代的吡啶环、可选择取代的吡啉环、嘧啶环或吡嗪环，R1'代表（1）其中，R1a'代表可选择取代的苯基或可选择取代的5-至10-成员杂环基，环B2代表键、-S-、-O-、-CO-、可选择取代的亚甲基基团或-NRa'-（Ra'代表氢原子或可选择取代的C1-6烷基基团），环B1'代表可选择进一步取代的6-至10-成员芳香碳氢环、或可选择进一步取代的5-至10-成员芳香杂环环，或者，L'和R1a'可以结合形成可选择取代的双环或三环融合杂环基，或（2）其中，R1b'代表可选择取代的苯基或可选择取代的5-至10-成员杂环基，环B2'代表可选择取代的苯环、可选择取代的吡啶环、可选择取代的嘧啶环、可选择取代的吡嗪环或可选择取代的吡啉环，环D'代表可选择进一步取代的5-或6-成员环，R2'代表氢原子或取代基，X'代表=N-或=CRb'-（Rb'代表氢原子或取代基），_ _ _ _ _代表Rb'和R2'可能形成，与它们各自相邻的碳原子和氮原子一起，当X'为=CRb'-时，形成可选择取代的5-至7-成员环，或其盐。
• N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents
  申请人：Brown Matthew Frank

  公开号：US20120258948A1

  公开（公告）日：2012-10-11

  The present invention is directed to a new class of hydroxamic acid derivatives of formula I, wherein the variables G, T, D, L, R 1 , R 2 , R 3 are as described herein, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections in a patient in need thereof.

  本发明涉及一种新的羟肟酸衍生物类别，其化学式为I，其中变量G，T，D，L，R1，R2，R3如本文所述，其用作LpxC抑制剂，更具体地用于治疗有需要的患者的细菌感染。
• N-linked hydroxamic acid derivatives useful as antibacterial agents
  申请人：Brown Matthew Frank

  公开号：US08664401B2

  公开（公告）日：2014-03-04

  The present invention is directed to a new class of hydroxamic acid derivatives of formula I, wherein the variables G, T, D, L, R1, R2, R3 are as described herein, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections in a patient in need thereof.

  本发明涉及一种新的羟肟酸衍生物类别，其化学式为I，其中变量G、T、D、L、R1、R2、R3如本文所述，它们的用途是LpxC抑制剂，更具体地用于治疗患有细菌感染的患者。
• Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity
  申请人：Hodous Brian L.

  公开号：US20140162983A1

  公开（公告）日：2014-06-12

  The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.

  本发明提供了新型嘧啶和吡啶化合物，其符合公式（I），公式（II），公式（III），公式（IV）和公式（V），以及它们的制备和用于治疗高增殖性疾病，包括但不限于癌症，狼疮，过敏性疾病，Sjogren's病和类风湿性关节炎。在优选实施例中，本发明描述了不可逆激酶抑制剂，包括但不限于布鲁顿酪氨酸激酶抑制剂。